China Pharma Holdings Grapples with Mounting Losses, Liquidity Concerns

TL;DR

**CPHI is bleeding cash and facing a going concern warning, making it a high-risk bet despite efforts to cut costs and boost sales.**

AI Summary

CHINA PHARMA HOLDINGS, INC. (CPHI) reported a significant net loss of $1,965,421 for the nine months ended September 30, 2025, a substantial improvement from the $3,511,933 net loss in the same period of 2024. Revenue declined to $2,918,271 for the nine months ended September 30, 2025, down from $3,394,934 in 2024, representing a 14.1% decrease. The company experienced a gross loss of $282,725 for the nine months ended September 30, 2025, compared to a gross loss of $1,825,059 in the prior year, indicating improved cost of revenue management. Operating expenses increased to $1,756,158 from $1,567,771 year-over-year, driven primarily by a rise in general and administrative expenses to $1,372,843 from $925,377. As of September 30, 2025, CPHI had cash and cash equivalents of $267,625 and an accumulated deficit of $46.0 million, with current liabilities exceeding current assets by $4.3 million. The company's Chairperson, CEO, and Interim CFO, Ms. Li, advanced an additional $0.27 million in fiscal 2025, bringing total related party borrowings to $1,413,340. Management plans to enhance its advance payment sales model, strengthen accounts receivable collection, explore strategic alternatives for nutrition products, and implement cost reduction measures across procurement, production, human resources, and marketing to address going concern doubts.

Why It Matters

CPHI's persistent net losses and significant accumulated deficit of $46.0 million, coupled with current liabilities exceeding current assets by $4.3 million, raise serious red flags for investors regarding its long-term viability. The company's reliance on its CEO for working capital infusions highlights a precarious financial position, potentially impacting its ability to invest in new products or retain key talent. For customers, this instability could lead to supply chain disruptions or reduced product innovation. In a competitive pharmaceutical market, CPHI's struggles could allow more financially robust competitors to gain market share, further eroding its position.

Risk Assessment

Risk Level: high — The company explicitly states "These conditions raise substantial doubt about its ability to continue as a going concern within one year." As of September 30, 2025, CPHI had only $267,625 in cash and cash equivalents, an accumulated deficit of $46.0 million, and current liabilities exceeding current assets by $4.3 million, indicating severe liquidity issues.

Analyst Insight

Investors should exercise extreme caution and consider divesting CPHI shares due to the explicit going concern warning and significant financial distress. The proposed mitigation plans are not considered probable of effective implementation by management, suggesting a high likelihood of continued operational challenges and potential insolvency.

Financial Highlights

debt To Equity

0.90

revenue

$2,918,271

operating Margin

-60.17%

total Assets

$15,804,793

total Debt

$7,490,796

net Income

$(1,965,421)

eps

$(0.57)

gross Margin

-9.7%

cash Position

$267,625

revenue Growth

-14.1%

Key Numbers

• $2,918,271 — Revenue (for the nine months ended September 30, 2025, down from $3,394,934 in 2024)
• $(1,965,421) — Net Loss (for the nine months ended September 30, 2025, an improvement from $(3,511,933) in 2024)
• $267,625 — Cash and Cash Equivalents (as of September 30, 2025, down from $626,879 as of December 31, 2024)
• $46.0 million — Accumulated Deficit (as of September 30, 2025, up from $44.0 million as of December 31, 2024)
• $4.3 million — Current Liabilities Exceeding Current Assets (as of September 30, 2025, indicating a significant working capital deficit)
• $1,413,340 — Borrowings from Related Parties (as of September 30, 2025, including an additional $0.27 million advanced by Ms. Li in fiscal 2025)
• $(0.57) — Basic and Diluted Loss Per Share (for the nine months ended September 30, 2025, an improvement from $(2.25) in 2024)
• 5,022,002 — Shares of Common Stock Outstanding (as of September 30, 2025, following a 1-for-10 reverse stock split effective April 15, 2025)
• $1,006,210 — Depreciation and Amortization (for the nine months ended September 30, 2025, down from $2,169,993 in 2024)
• $506,879 — Inventory Write-off (for the nine months ended September 30, 2025, up from $463,984 in 2024)

Key Players & Entities

• CHINA PHARMA HOLDINGS, INC. (company) — registrant
• Onny Investment Limited (company) — wholly-owned subsidiary
• Hainan Helpson Medical & Biotechnology Co., Ltd (company) — wholly-owned subsidiary
• Ms. Li (person) — Chairperson, Chief Executive Officer and Interim Chief Financial Officer
• National Medical Products Administration (regulator) — approves pharmaceutical products in PRC
• Securities and Exchange Commission (regulator) — filing oversight
• $46.0 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $4.3 million (dollar_amount) — current liabilities exceeding current assets as of September 30, 2025
• $1,413,340 (dollar_amount) — total borrowings from related parties as of September 30, 2025
• $2,446,400 (dollar_amount) — issuance of common stock for intangible assets during the nine months ended September 30, 2025

FAQ

Risk Factors

• Working Capital Deficit [high — financial]: As of September 30, 2025, CPHI has a working capital deficit of $4.3 million, with current liabilities of $6,622,806 exceeding current assets of $2,329,427. This indicates a short-term liquidity challenge that could impact the company's ability to meet its immediate obligations.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $46.0 million as of September 30, 2025, an increase from $44.0 million at the end of 2024. This substantial deficit highlights a history of unprofitability and raises concerns about the company's long-term financial viability.
• Reliance on Related Party Financing [medium — financial]: Borrowings from related parties stand at $1,413,340 as of September 30, 2025, including an additional $0.27 million advanced by Ms. Li in fiscal 2025. This reliance on financing from key personnel introduces potential conflicts of interest and dependence on personal financial support.
• Declining Revenue [medium — operational]: Revenue for the nine months ended September 30, 2025, decreased by 14.1% to $2,918,271 from $3,394,934 in the prior year. This downward trend in sales suggests potential issues with market demand, product competitiveness, or sales execution.
• Inventory Write-offs [medium — operational]: Inventory write-offs increased to $506,879 for the nine months ended September 30, 2025, up from $463,984 in the same period of 2024. This rise indicates potential issues with inventory management, obsolescence, or valuation, impacting profitability.
• Increased Operating Expenses [medium — operational]: Operating expenses rose to $1,756,158 from $1,567,771 year-over-year, primarily driven by a significant increase in general and administrative expenses to $1,372,843 from $925,377. This surge in G&A costs, despite declining revenue, is a concern for operational efficiency.
• New Accounting Standards Adoption [low — regulatory]: CPHI is evaluating the impact of adopting new accounting standards, including ASU 2024-04 (Debt) and ASU 2025-01 (Income Statement). Changes in accounting policies can affect reported financial results and require careful implementation and disclosure.
• Decreasing Cash Position [high — financial]: Cash and cash equivalents decreased to $267,625 as of September 30, 2025, from $626,879 as of December 31, 2024. This significant reduction in liquidity, coupled with the working capital deficit, heightens concerns about the company's ability to fund operations.

Industry Context

CPHI operates in the pharmaceutical and healthcare sector, which is characterized by intense competition, stringent regulatory oversight, and evolving consumer health trends. The industry requires significant investment in research and development, manufacturing, and marketing. Companies often face challenges related to product lifecycle management, generic competition, and pricing pressures. The shift towards specialized nutrition products also presents both opportunities and competitive hurdles.

Regulatory Implications

As a pharmaceutical company, CPHI is subject to extensive regulations from bodies like the FDA concerning product safety, efficacy, and manufacturing standards. Changes in accounting standards, such as those CPHI is evaluating, can also impact financial reporting and compliance. Failure to adhere to these regulations can result in fines, product recalls, and reputational damage.

What Investors Should Do

1. Monitor cash burn and liquidity closely.
2. Evaluate the effectiveness of cost reduction strategies.
3. Assess the sustainability of revenue generation.
4. Understand the terms and risks associated with related party financing.
5. Analyze the strategic alternatives for nutrition products.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reporting period for the current 10-Q, showing a reduced net loss but declining revenue and increased G&A expenses.
• 2025-04-15: 1-for-10 reverse stock split effective — Adjusted the number of outstanding shares to 5,022,002, impacting per-share metrics and potentially investor perception.
• 2025-01-01: ASU 2025-01 effective date for early adoption — Company is evaluating the impact of this accounting update related to expense disaggregation.
• 2024-12-15: ASU 2024-04 effective date for early adoption — Company is evaluating the impact of this accounting update related to convertible debt instruments.
• 2024-11-01: FASB issued ASU 2024-04 — Introduced new guidance on induced conversions of convertible debt instruments.
• 2024-01-01: Nine months ended September 30, 2024 — Prior year comparative period, showing a larger net loss and higher revenue.

Glossary

Accumulated Deficit

The total cumulative net losses of a company that have not been offset by net income or additional paid-in capital. It represents a history of unprofitability. (CPHI has a significant accumulated deficit of $46.0 million, indicating a long-term struggle to achieve profitability.)

Working Capital

The difference between a company's current assets and current liabilities. Positive working capital indicates a company's ability to meet its short-term obligations. (CPHI has a negative working capital of $4.3 million, signaling potential liquidity issues.)

Related Party Borrowings

Loans or advances made by individuals or entities that have a close relationship with the company, such as officers, directors, or major shareholders. (CPHI relies on $1,413,340 in related party borrowings, highlighting dependence on insiders for financing.)

Inventory Write-off

The reduction in the value of inventory when it becomes obsolete, damaged, or unsellable, resulting in a charge against earnings. (An increase in inventory write-offs to $506,879 suggests potential issues with inventory management or product obsolescence.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (CPHI executed a 1-for-10 reverse stock split, which reduced the share count but does not change the company's underlying value.)

Gross Loss

Occurs when the cost of goods sold exceeds the revenue generated from sales. It indicates that the company is not covering its direct production costs with its sales revenue. (CPHI reported a gross loss of $282,725, an improvement from the prior year but still indicating challenges in pricing or cost of goods sold.)

Operating Expenses

Costs incurred by a company in its normal business operations, excluding the cost of goods sold. This includes selling, general, and administrative (SG&A) expenses. (Operating expenses increased to $1,756,158, driven by higher G&A, which is a concern given declining revenue.)

Contract Liabilities

Obligations to transfer goods or services to a customer for which the company has received consideration from the customer. Also known as deferred revenue. (Contract liabilities were $120,912, representing revenue that has been received but not yet earned.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, CHINA PHARMA HOLDINGS, INC. has significantly reduced its net loss from $(3,511,933) to $(1,965,421), indicating improved cost management or revenue recovery potential. However, revenue has declined by 14.1% to $2,918,271, and operating expenses, particularly G&A, have increased. While the gross loss has narrowed, the overall financial picture remains challenging due to a growing accumulated deficit and a deteriorating cash position, alongside a persistent working capital deficit.

Key Financial Figures

• $0.01 — were 5,022,002 shares of common stock, $0.01 par value per share, issued and outstan

Filing Documents

• ea0263576-10q_china.htm (10-Q) — 596KB
• ea026357601ex31-1_china.htm (EX-31.1) — 10KB
• ea026357601ex31-2_china.htm (EX-31.2) — 10KB
• ea026357601ex32-1_china.htm (EX-32.1) — 5KB
• 0001213900-25-109203.txt ( ) — 4066KB
• cphi-20250930.xsd (EX-101.SCH) — 38KB
• cphi-20250930_cal.xml (EX-101.CAL) — 40KB
• cphi-20250930_def.xml (EX-101.DEF) — 189KB
• cphi-20250930_lab.xml (EX-101.LAB) — 374KB
• cphi-20250930_pre.xml (EX-101.PRE) — 214KB
• ea0263576-10q_china_htm.xml (XML) — 395KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 1 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

OTHER INFORMATION

PART II OTHER INFORMATION 30 Item 6. Exhibits 30 i

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES TABLE OF CONTENTS Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (Unaudited) 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Stockholders' Equity for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 5 Notes to Condensed Consolidated Financial Statements (Unaudited) 6 1 CHINA PHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, December 31, 2025 2024 ASSETS Current Assets: Cash and cash equivalents $ 267,625 $ 626,879 Banker's acceptances 26,697 18,642 Trade accounts receivable, less allowance for credit losses of $ 69,876 and $ 13,587,182 , respectively 224,638 232,140 Other receivables, less allowance for credit losses of $ 32,511 and $ 28,447 , respectively 61,275 30,286 Advances to suppliers 23,883 14,960 Inventories 1,649,682 2,266,154 Prepaid expenses 75,627 81,328 Total Current Assets 2,329,427 3,270,389 Property, plant and equipment, net 4,502,479 4,883,401 Right-of-use assets 197,851 38,298 Intangible assets, net 8,775,036 6,695,436 TOTAL ASSETS $ 15,804,793 $ 14,887,524 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Trade accounts payable $ 588,739 $ 225,106 Accrued expenses 170,426 247,159 Other payables 2,303,183 2,182,982 Contract liabilities 120,912 162,208 Borrowings from related parties 1,413,340 1,144,985 Lease liabilities 70,326 39,323 Current portion of lines of credit 1,955,880 1,015,525 Total Current Liabilities 6,622,806 5,017,288 Non-current Liabilities: Lines of credit, net of current portion - 1,391,13

Financial Statements but will require certain additional disclosures

Financial Statements but will require certain additional disclosures. 7 CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (UNAUDITED) In November 2024, the FASB issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments. The ASU provides additional guidance on whether induced conversion or extinguishment accounting should be applied to certain settlements of convertible debt instruments that do not occur in accordance with the instruments' preexisting terms. The ASU requires entities to apply a preexisting contract approach. To qualify for induced conversion accounting under this approach, the inducement offer is required to preserve the form of consideration and result in an amount of consideration that is no less than that issuable pursuant to the preexisting conversion privileges. ASU 2024-04 clarifies how entities should assess the form and amount of consideration when applying this approach. In addition, the new ASU clarifies that induced conversion accounting can be applied to settlements of certain convertible debt instruments that are not currently convertible as long as the instrument contained a substantive conversion feature as of both its issuance date and the inducement offer acceptance date. The amendments in the ASU are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the impact the adoption of ASU 2024-04 will have on its consolidated financial statements and related disclosures. In January 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2025-01 — Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. This ASU am

View Full Filing

View this 10-Q filing on SEC EDGAR